Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jose de Leon

Showing results (81-90 of 381) with videos related to

Pageof 39
Sort By:
Pharmacogenomics|July 28, 2016
CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatientsDustin B Stephens, Jose de Leon
Schizophrenia Research|July 10, 2007
Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategyJose de Leon, Francisco J Diaz
Clinical Pharmacology and Therapeutics|April 30, 2004
Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence?Peter J Wedlund, Jose de Leon
Psychosomatics|March 20, 2012
Lower gastrointestinal bleeding and paroxetine use: two case reportsHilario Blasco-Fontecilla, Jose de Leon
Pharmacogenomics|April 21, 2020
Is there a future for <i>CYP1A2</i> pharmacogenetics in the optimal dosing of clozapine?Can-Jun Ruan, Jose de Leon
Journal of Clinical Epidemiology|January 26, 2016
Pathophysiology and clinical trials have limitations in some areas of medicine: focus on psychiatry (letter commenting: J Clin Epidemiol. 2014;67(4):361-363.)Jose de Leon, Dustin B Stephens
Human Genetics|December 23, 2011
Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findingsJose de Leon, Francisco J Diaz
Psychotherapy and Psychosomatics|February 10, 2017
Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on AdherenceCarlos De Las Cuevas, Jose de Leon
Journal of Clinical Psychopharmacology|August 16, 2003
Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizersJose de Leon, Lori Dinsmore, Peter Wedlund
Expert Review of Clinical Pharmacology|October 1, 2024
Clozapine for persons with neurodevelopmental disorders: a systematic review and expert recommendations for clinical practiceHélène Verdoux, Clélia Quiles, Jose de Leon
Pageof 39

Showing results (81-90 of 381) with videos related to

Sort By:
Pageof 39
Pharmacogenomics|July 28, 2016
CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatientsDustin B Stephens, Jose de Leon
Schizophrenia Research|July 10, 2007
Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategyJose de Leon, Francisco J Diaz
Clinical Pharmacology and Therapeutics|April 30, 2004
Cytochrome P450 2D6 and antidepressant toxicity and response: what is the evidence?Peter J Wedlund, Jose de Leon
Psychosomatics|March 20, 2012
Lower gastrointestinal bleeding and paroxetine use: two case reportsHilario Blasco-Fontecilla, Jose de Leon
Pharmacogenomics|April 21, 2020
Is there a future for <i>CYP1A2</i> pharmacogenetics in the optimal dosing of clozapine?Can-Jun Ruan, Jose de Leon
Journal of Clinical Epidemiology|January 26, 2016
Pathophysiology and clinical trials have limitations in some areas of medicine: focus on psychiatry (letter commenting: J Clin Epidemiol. 2014;67(4):361-363.)Jose de Leon, Dustin B Stephens
Human Genetics|December 23, 2011
Genetics of schizophrenia and smoking: an approach to studying their comorbidity based on epidemiological findingsJose de Leon, Francisco J Diaz
Psychotherapy and Psychosomatics|February 10, 2017
Reviving Research on Medication Attitudes for Improving Pharmacotherapy: Focusing on AdherenceCarlos De Las Cuevas, Jose de Leon
Journal of Clinical Psychopharmacology|August 16, 2003
Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizersJose de Leon, Lori Dinsmore, Peter Wedlund
Expert Review of Clinical Pharmacology|October 1, 2024
Clozapine for persons with neurodevelopmental disorders: a systematic review and expert recommendations for clinical practiceHélène Verdoux, Clélia Quiles, Jose de Leon
Pageof 39